Top Clinical Trials companies in United Kingdom by Total Assets

This ranking features the top 12 Clinical Trials companies in United Kingdom ranked by Total Assets, totalling a Total Assets of USD 2.59 B, for January 15, 2025.
#
Name
Total Assets
Reported Date
Stock Price
Change
Price (30 days) Country
1
USD 597.00 M
Dec. 31, 2023 USD 28.56 -4.90%

United Kingdom

2
USD 595.34 M
Dec. 31, 2023 USD 14.81 -2.31%

United Kingdom

3
USD 375.38 M
Dec. 31, 2023 USD 2.21 -3.91%

United Kingdom

4
USD 360.25 M
Dec. 31, 2023 USD 14.84 -2.75%

United Kingdom

5
USD 214.51 M
Dec. 31, 2023 USD 0.95 0.80%

United Kingdom

6
USD 119.37 M
Dec. 31, 2023 USD 5.61 -4.92%

United Kingdom

7
USD 105.89 M
Dec. 31, 2023 USD 0.21 6.16%

United Kingdom

8
USD 93.12 M
Dec. 31, 2023 USD 0.62 -2.80%

United Kingdom

9
USD 66.50 M
Dec. 31, 2023 USD 3.06 -8.38%

United Kingdom

10
USD 35.38 M
Dec. 31, 2023 USD 1.04 1.96%

United Kingdom

11
USD 18.10 M
Dec. 31, 2023 USD 0.49 0.09%

United Kingdom

12
USD 5.33 M
Dec. 31, 2023 USD 0.04 0.09%

United Kingdom

Frequently Asked Questions
  • Which Clinical Trials company in United Kingdom has the highest Total Assets ?

    The Clinical Trials company in United Kingdom with the highest Total Assets is Immunocore Holdings plc (NasdaqGS: IMCR) at USD 597.00 M.

  • Which Clinical Trials company in United Kingdom has the lowest Total Assets ?

    The Clinical Trials company in United Kingdom with the lowest Total Assets is GENinCode plc (LSE: GENI.L) at USD 5.33 M.